Bio
Dr. Wang is a board-certified, fellowship-trained neurocritical care specialist at Stanford Health Care. He is an Adjunct Clinical Assistant Professor in the Department of Neurology & Neurological Sciences at Stanford University School of Medicine. He also serves as Medical Director of Clinical Development at Denali Therapeutics, a biotechnology company based in South San Francisco.
Dr. Wang's clinical, research, and medical education interests include stroke, traumatic brain and spinal cord injury, and secondary neurodegeneration following acute brain injury. He provides care for critically ill patients with neurological illnesses in the intensive care unit (ICU) at Stanford Hospital and teaches fellows, residents, and medical students how to deliver critical neurological care.
Dr. Wang has received research awards and grants from the National Institutes of Health, the American Heart Association/American Stroke Association, the American Academy of Neurology, and the Alzheimer's Association. He has published in several top peer-reviewed journals, including Proceedings of the National Academy of Sciences, Journal of Cell Biology, and Journal of Neuroscience, and has presented his research at national and international conferences. He also serves as an ad hoc reviewer for a number of publications, including Cell, Neuron, Nature, and Science.
In his role in clinical development, Dr. Wang draws on his expertise in neurological care and translational neuroscience to help advance novel therapies from research into clinical practice, with a focus on improving outcomes for patients with acute and chronic degenerative neurological conditions.
Dr. Wang is a member of the American Academy of Neurology, American Heart Association, Neurocritical Care Society, Society of Critical Care Medicine, and Society for Neuroscience.
